Pharmaceutical Technology

MAY 30, 2023

Bisphosphonates are drugs that slow the progression of bone loss. EffRx has received several European regulatory approvals for drugs in its portfolio. Alkindi is one of EffRx’s three marketed drugs. In Italy, Abiogen began distributing its bisphosphonates in 2014 and has since seen some successful drug approvals.

Contract Manufacturing 130

Contract Manufacturing Clinical Supply Licensing Licensing 130

pharmaphorum

NOVEMBER 2, 2022

CSL’s vaccines unit CSL Seqirus division is paying Arcturus $200 million upfront to gain access to its self-amplifying mRNA technology platform and exclusive licenses to several vaccine candidates, with another $4.3 billion on offer in milestones if the programmes meet development and commercial objectives.

Vaccination 52

Vaccination Vaccine Immune Response Gene Therapy 52

The Pharma Data

JANUARY 24, 2021

Food and Drug Administration (“FDA”) approval. Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases. PharmaDrug Inc.

Drugs 52

Drugs Containment Development Sales 52

The Pharma Data

JANUARY 10, 2021

for the treatment of plaque psoriasis, became the first drug based on MorphoSys’ antibody technology to receive regulatory approval. In 2017, Tremfya (R) , developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., In July 2020, the U.S.

Containment 52

Containment Clinical Development Antibody Development 52

The Pharma Data

NOVEMBER 22, 2020

MP0420 is subject to an option and license agreement with Novartis AG to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program. DARPin® therapeutics have been clinically validated through to the registrational stage. Chief Medical Officer of Molecular Partners. About Molecular Partners AG.

Trials 40

Trials Protein Clinical Trials Clinical Trials 40

The Pharma Data

OCTOBER 27, 2020

Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19. During the clinical development stage, Molecular Partners will provide clinical supply.

Development 52

Development Protein Manufacturing Medicine 52

The Pharma Data

AUGUST 15, 2021

Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company, and Pfizer Inc. VTX-801 is a novel investigational gene therapy to be evaluated in a Phase 1/2 clinical trial to determine the safety, tolerability, and pharmacological activity of a single intravenous infusion in adult patients with Wilson Disease. About VTX-801.

Gene Therapy 52

Gene Therapy Gene Clinical Trials Clinical Trials 52